Research progress on the role of probiotics in acute liver failure
Chen Xue,Qingfei Chu,Lanjuan Li
DOI: https://doi.org/10.2478/jtim-2021-0052
2022-01-01
Journal of Translational Internal Medicine
Abstract:Acute liver failure (ALF) is a relatively rare disease with a high fatality rate. As early as 1970, ALF was first described as fulminant liver failure, but this term has now been abandoned.[1] ALF is a complex disease involving multiple organ functions. As the course of the disease progresses, cerebral edema, renal failure, respiratory failure, hemodynamic disorders, and coagulation disorders may occur. The main manifestations of ALF are prolongation of prothrombin time/ international normalized ratio (PT/INR), decreased mental function, peripheral vasodilatation, systemic inflammatory response syndrome, and eventually multiple organ failure. In different parts of the world, the causes of ALF are different. In developed countries, paracetamol toxicity, ischemia, drug-induced liver injury, hepatitis B virus, and autoimmunity are the five most common causes of ALF. In contrast, viral hepatitis A, B, and E are the main causes of ALF in developing countries. When severe liver dysfunction occurs, in addition to supportive treatment and care for related complications, liver transplantation is still the ultimate treatment for ALF. However, due to the limitations of transplantation conditions, less than 10% of liver transplant patients receive transplantation treatment because of ALF.[2-4]